Your Messages Inbox
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Cell Therapeutics, Inc. released updated 18–month follow–up clinical data for its phase III EXTEND trial of pixantrone for patients with advanced, relapsed or refractory, aggressive non–Hodgkin's lymphoma. Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Primary endpoint reached in Active Biotechs TASQ Phase II clinical trial in prostate cancer patients
Active Biotech, 12/15/09
Article Search
Sponsor